14.37

1.84% -0.27

Enanta Pharmaceuticals Inc (ENTA)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$14.64

Offen:

$14.63

24-Stunden-Volumen:

190.94K

Relative Volume:

0.27

Marktkapitalisierung:

$414.76M

Einnahmen:

$66.59M

Nettoeinkommen (Verlust:

$-104.93M

KGV:

-2.903

EPS:

-4.95

Netto-Cashflow:

$-96.48M

1W Leistung:

+0.91%

1M Leistung:

+24.85%

6M Leistung:

+89.58%

1J Leistung:

+66.32%

1-Tages-Spanne:

$14.19

$14.79

1-Wochen-Bereich:

$13.75

$14.79

52-Wochen-Spanne:

$4.09

$15.34

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Firmenname

Enanta Pharmaceuticals Inc

Sektor

Healthcare (1124)

Branche

Biotechnology (627)

Telefon

617 607 0800

Adresse

4 KINGSBURY AVENUE, WATERTOWN, MA

Mitarbeiter

120

Twitter

@EnantaPharma

Nächster Verdiensttermin

2025-02-10

Neueste SEC-Einreichungen

ENTA's Discussions on Twitter

Vergleichen Sie ENTA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ENTA Enanta Pharmaceuticals Inc	14.37	422.55M	66.59M	-104.93M	-96.48M	-4.95
VRTX Vertex Pharmaceuticals Inc	444.64	110.88B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	726.21	72.79B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	890.11	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	404.46	54.85B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	189.85	41.41B	447.02M	-1.18B	-906.14M	-6.1812

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-11-14	Eingeleitet	JP Morgan	Overweight
2025-10-01	Hochstufung	Jefferies	Hold → Buy
2025-07-28	Fortgesetzt	H.C. Wainwright	Buy
2023-08-09	Herabstufung	JP Morgan	Neutral → Underweight
2023-08-08	Herabstufung	Jefferies	Buy → Hold
2022-12-09	Eingeleitet	H.C. Wainwright	Buy
2022-07-06	Hochstufung	Evercore ISI	In-line → Outperform
2022-06-01	Hochstufung	Evercore ISI	Underperform → In-line
2021-10-07	Eingeleitet	Jefferies	Buy
2021-09-09	Eingeleitet	SVB Leerink	Mkt Perform
2021-01-29	Hochstufung	JP Morgan	Underweight → Neutral
2020-11-24	Eingeleitet	Evercore ISI	Underperform
2020-08-28	Fortgesetzt	ROTH Capital	Buy
2020-08-26	Eingeleitet	Piper Sandler	Overweight
2020-07-27	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2020-03-17	Hochstufung	Robert W. Baird	Neutral → Outperform
2019-11-22	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2019-09-26	Herabstufung	JP Morgan	Neutral → Underweight
2019-05-24	Eingeleitet	Wolfe Research	Outperform
2019-04-23	Hochstufung	Berenberg	Hold → Buy
2018-12-13	Eingeleitet	Berenberg	Hold
2018-06-06	Eingeleitet	ROTH Capital	Buy
2018-02-08	Herabstufung	JP Morgan	Overweight → Neutral
2018-01-02	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2017-11-21	Bestätigt	RBC Capital Mkts	Outperform
2017-09-15	Eingeleitet	RBC Capital Mkts	Outperform
2017-07-11	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2016-04-28	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2016-02-09	Bestätigt	Barclays	Underweight
2015-10-23	Herabstufung	Barclays	Equal Weight → Underweight
2015-10-23	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform

Alle ansehen

Enanta Pharmaceuticals Inc Aktie (ENTA) Neueste Nachrichten

Dec 08, 2025

Have Insiders Sold Enanta Pharmaceuticals Shares Recently? - simplywall.st

Dec 08, 2025

Enanta Pharmaceuticals falls on public offering of common stock - MSN

Dec 08, 2025

Dec 06, 2025

Enanta Pharma chief medical officer sells $11k in stock By Investing.com - Investing.com Canada

Dec 06, 2025

Dec 05, 2025

Enanta Pharma CBO Luu sells $19,836 in stock By Investing.com - Investing.com Canada

Dec 05, 2025

Enanta Pharma chief product officer sells $30k in stock By Investing.com - Investing.com UK

Dec 05, 2025

Will Enanta Pharmaceuticals Inc. (9EP) stock extend growth storyJuly 2025 Intraday Action & Daily Profit Focused Screening - Newser

Dec 05, 2025

Dec 04, 2025

Can Enanta Pharmaceuticals Inc. (9EP) stock survive global slowdownJuly 2025 PostEarnings & Consistent Profit Focused Trading Strategies - Newser

Dec 04, 2025

Is Enanta Pharmaceuticals Inc. (9EP) stock nearing a technical breakout - Newser

Dec 04, 2025

Is Enanta Pharmaceuticals Inc. stock a top momentum playQuarterly Market Summary & Risk Controlled Daily Trade Plans - Newser

Dec 04, 2025

Dec 03, 2025

VP Or Surrenders 753 Of Enanta Pharmaceuticals Inc [ENTA] - TradingView

Dec 03, 2025

ENTA: RSV and immunology pipelines advance with key candidates and pivotal trials planned for 2026 - TradingView

Dec 03, 2025

Dec 02, 2025

Is Enanta Pharmaceuticals Inc. (9EP) stock a defensive play amid uncertainty - Newser

Dec 02, 2025

Nov 30, 2025

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Nov 30, 2025

Nov 29, 2025

Certain Options of Enanta Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025. - marketscreener.com

Nov 29, 2025

Certain Common Stock of Enanta Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025. - marketscreener.com

Nov 29, 2025

Does Enanta Pharmaceuticals Inc. stock trade at a discount to peersTake Profit & Free Safe Entry Trade Signal Reports - BỘ NỘI VỤ

Nov 29, 2025

Portfolio Recap: What makes Enanta Pharmaceuticals Inc. stock attractive to growth funds2025 Winners & Losers & Risk Adjusted Swing Trade Ideas - BỘ NỘI VỤ

Nov 29, 2025

Enanta Pharmaceuticals Inc Stock Analysis and ForecastMarket Capitalization Trends & Free Unmatched Market Performance - earlytimes.in

Nov 29, 2025

Nov 27, 2025